ALZHEIMER’S DISEASE: ADVANCING THERAPEUTICS TOWARDS THE CLINIC
JUNE 16-17, 1997, L’ENFANT PLAZA
WASHINGTON, DC
PATHOGENESIS OF ALZHEIMER’S DISEASE
Molecular Analysis of the Presenilin Genes: Dr. Rudolf Tanzi, Harvard
Medical School (Confirmed)
The Vasoactivity of b-Amyloid Peptides: Dr. Mike Mullan, University of
South Florida (Confirmed)
Epidemiological Differences, Racial Comparisons With Asians and
Alzheimer’s Disease: Dr. Lon White, NIA-Asia-Pacific Office
(Confirmed)
The Link of ApoE4 with Acetylcholine Defects: Dr. Judes Poirier,
McGill Centre for Studies in Aging (Invited)
Presenlin Proteins in Alzheimer’s Disease: Dr. Martin Citron, Harvard
Medical School (Confirmed)
MEMORY ENHANCEMENT
Calcium Hypothesis on Aging and Dementia, Dr. John F. Disterhoft,
Northwestern University (Confirmed)
Cholinergic Channel Modulator as a Novel Therapeutic Strategy for
Alzheimer’s Disease: Dr. M.W. Holladay, Abbott Laboratories (to
invite?)
Aricept as a new Therapeutics for the Treatment of Alzheimer’s, Dr.
Sharon L. Rogers, Eisai, Inc.(Invited)
ABT 418 patch as a treatment for Alzheimer’s Disease: Dr. Paul Clark,
Abbott Laboratories (Invited)
Nicotine Receptor for Dementia: SIBIA (inquiry Sent)
CX516 Memory Enhancer: Dr. Gary Lynch, UCI, Cortex Pharmaceuticals
(Invited)
Mutrifonet for Alzheimer’s Disease: Dr. Richard Finelli, Bayer
(inquiry Sent)
BETA-AMYLOID THERAPEUTICS
Amyloidogenic Protein: Common Element Interaction as a target for
Anti-Amyloid Therapy, Dr. Robert Kisilevsky, Neurochem, Inc., Queen’s
University (Confirmed)
Protease Inhibitors: Challenges to AD Drug Development, Dr. Kevin M.
Felsenstein, Bristol-Myers Squibb Pharmaceutical Research Institute
(Confirmed)
Probing Molecular Mechanisms of Amyloid Fibril Formation: On the
Pathway to
Therapeutic Agents, Dr. Harry LeVine, III, Parke-Davis Pharmaceutical
Research Division, Warner Lambert Company (Confirmed)
Salen Manganese Complexes: Combine Superoxide Dusmutase/Catalase
Mimics that are Protective in Models for Neurological Disorders, Dr.
Susan R. Doctrow, Eukarion, Inc. (Confirmed)
Therapeutics for Alzheimer’s Disease: Dr. Dale Schenk, Athena
(Invited)
Ab42-Therapeutic Target: Dr. Steven G. Younkin, Mayo
Clinic-Jacksonville (Invited)
Protease Inhibitor for Amyloidosis: Dr. Bob Siman, Cephalon, Inc.
(Inquiry sent)
NOVEL TARGETS FOR THERAPEUTIC INTERVENTION
Therapeutics Targeting ApoE4, Glaxo Corporation (Invited)
The use of Complement Inhibitors: Dr. Robert Frederickson, Gliatech
Corporation ( inquiry sent)
CRF Agonist as a Therapeutic, DHEA as a Neuroprotectant: Dr. P.
Sunkara, Neurocrine ( inquiry sent)
Therapeutics Targeting ApoE: Dr. Robert McBurney, Cambridge
Neuroscience ( inquiry sent)
Proteins that Interact with Beta-Amyloid Peptide and Presenilin I: Dr.
Sudhir Sahasrabudhe, Hoechst Marion Roussel, Inc. (Confirmed)
For registration and hotel information, please contact:
Cambridge Healthtech Institute
1037 Chestnut Street
Newton Upper Falls, MA 02164
USA
Phone: 617-630-1300
Fax: 617-630-1325
e-mail: chi at healthtech.comhttp://www.healthtech.com/conferences/
______________________________
Cambridge Healthtech Institute
1037 Chestnut Street
Newton Upper Falls, MA 02164
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
tel: 617.630.1300
fax: 617.630.1325
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
inquiries at healthtech.com
World Wide Web http://www.healthtech.com/conferences
